Open AccessMechanisms of Acquired In Vivo and In Vitro Resistance to Voriconazole by Candida krusei following Exposure to Suboptimal Drug Concentration
Author(s) -
Elisabete Ricardo,
Frédéric Grenouillet,
Isabel M. Miranda,
Raquel M. Silva,
Guilluame Eglin,
Nadège Devillard,
Acácio Gonçalves Rodrigues,
Cidália Pina-Vaz
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01651-19
Subject(s) - candida krusei , voriconazole , in vivo , in vitro , fluconazole , microbiology and biotechnology , drug resistance , urine , biology , pharmacology , chemistry , antifungal , biochemistry
Five Candida krusei isolates (susceptible and resistant) recovered from the urine of a kidney transplant patient treated with voriconazole (VRC) 200 mg twice daily for 20 days were studied. Eight unrelated clinical isolates of C. krusei were exposed in vitro to VRC 0.001 μg/ml for 30 days. Development of VRC transient resistance occurred in vivo , and induction of permanent resistance occurred in vitro Mostly, ABC1 and ERG11 genes were overexpressed, and a homozygous T418C mutation in the ERG11 gene was found.